Powerup Acquisition CORP Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Aspire Biopharma Holdings, Inc. Director Donald G. Fell filed an amendment to his beneficial ownership statement, clarifying that recent transactions were purchases of company common stock, not dispositions.
Donald G. Fell, a Director at Aspire Biopharma Holdings, Inc., has acquired 20,000 shares of the company's common stock through open market purchases in early June 2025.
PowerUp Acquisition Corp. secures a $500,000 loan facility from Blackstone to support its merger with Aspire Biopharma.
PowerUp Acquisition Corp. and Aspire Biopharma agree to extend the deadline for delivering disclosure schedules as part of their merger agreement to allow for additional due diligence.
425: PowerUp Acquisition Corp. Agrees to $1 Million Fee for Sponsor's Risk in Terminated Visiox Deal
PowerUp Acquisition Corp. will pay its sponsor, SRIRAMA Associates, LLC, a $1 million fee upon the successful closing of the Aspire Biopharma business combination to compensate for the risk taken in a prior, terminated deal with Visiox Pharmaceuticals.
PowerUp Acquisition Corp. and Aspire Biopharma amend their merger agreement to adjust the merger consideration, equity incentive plan size, and extend the disclosure schedule delivery date.
PowerUp Acquisition Corp. has entered into a definitive agreement to merge with Aspire Biopharma, valuing the combined entity at approximately $316.8 million.
PowerUp Acquisition Corp. and Visiox Pharmaceuticals amend their merger agreement, extending the outside date to June 30, 2024, and modifying financial conditions to facilitate the transaction.